Clinical Trial Update: Mifepristone (RU-486) in Androgen Independent Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of mifepristone (RU-486) in androgen-independent prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Mifepristone (RU-486) (mifepristone)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Prostate Cancer, Adenocarcinoma of Prostate | Phase 2 | Status: COMPLETED